{"title":"住院癌症患者使用日本草药汉方药的趋势:一项14年的全国分析。","authors":"Chikako Iwai, Takaaki Konishi, Shotaro Aso, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga","doi":"10.1007/s10147-025-02866-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kampo medicine (Japanese herbal medicine) is often used to manage the side effects of cancer treatment and improve quality of life. However, nationwide trends in Kampo use among inpatients with cancer in Japan remain poorly understood. This study aimed to examine the temporal trends and clinical practice patterns of Kampo prescriptions among inpatients with cancer between 2010 and 2023, with a focus on their use in acute or severe conditions.</p><p><strong>Methods: </strong>This retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including over 6.8 million hospitalizations for five major cancer types (breast, colorectal, gastric, lung, and prostate)between July 2010 and March 2023. Kampo use was identified from in-hospital prescription data. Prescription trends and patient characteristics were analyzed.</p><p><strong>Results: </strong>Kampo medicines were prescribed in 13.6% of hospitalizations, more commonly among older adults and patients with colorectal cancer. The overall prescription proportion increased from 2010 to 2017 before plateauing. The top five prescribed Kampo medicines were Dai-ken-chu-to, Gosha-jinki-gan, Rikkunshi-to, Shakuyaku-kanzo-to, and Hange-shashin-to. Prescription patterns varied by age group, cancer type, cancer stage, disease status, and cause of hospitalization. Dai-ken-chu-to use shifted from postoperative to chronic care, while Gosha-jinki-gan prescriptions gradually declined.</p><p><strong>Conclusions: </strong>Kampo prescription patterns among inpatients with cancer have changed over the past fourteen years, reflecting changes in patient demographics and treatment strategies. Kampo medicines appear to be selectively used as supportive care tailored to specific clinical situations. These findings highlight the evolving role of traditional medicine in modern cancer care in Japan.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in the use of Japanese herbal Kampo medicine in inpatients with cancer: a 14-year nationwide analysis.\",\"authors\":\"Chikako Iwai, Takaaki Konishi, Shotaro Aso, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga\",\"doi\":\"10.1007/s10147-025-02866-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Kampo medicine (Japanese herbal medicine) is often used to manage the side effects of cancer treatment and improve quality of life. However, nationwide trends in Kampo use among inpatients with cancer in Japan remain poorly understood. This study aimed to examine the temporal trends and clinical practice patterns of Kampo prescriptions among inpatients with cancer between 2010 and 2023, with a focus on their use in acute or severe conditions.</p><p><strong>Methods: </strong>This retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including over 6.8 million hospitalizations for five major cancer types (breast, colorectal, gastric, lung, and prostate)between July 2010 and March 2023. Kampo use was identified from in-hospital prescription data. Prescription trends and patient characteristics were analyzed.</p><p><strong>Results: </strong>Kampo medicines were prescribed in 13.6% of hospitalizations, more commonly among older adults and patients with colorectal cancer. The overall prescription proportion increased from 2010 to 2017 before plateauing. The top five prescribed Kampo medicines were Dai-ken-chu-to, Gosha-jinki-gan, Rikkunshi-to, Shakuyaku-kanzo-to, and Hange-shashin-to. Prescription patterns varied by age group, cancer type, cancer stage, disease status, and cause of hospitalization. Dai-ken-chu-to use shifted from postoperative to chronic care, while Gosha-jinki-gan prescriptions gradually declined.</p><p><strong>Conclusions: </strong>Kampo prescription patterns among inpatients with cancer have changed over the past fourteen years, reflecting changes in patient demographics and treatment strategies. Kampo medicines appear to be selectively used as supportive care tailored to specific clinical situations. These findings highlight the evolving role of traditional medicine in modern cancer care in Japan.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-025-02866-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02866-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Trends in the use of Japanese herbal Kampo medicine in inpatients with cancer: a 14-year nationwide analysis.
Background: Kampo medicine (Japanese herbal medicine) is often used to manage the side effects of cancer treatment and improve quality of life. However, nationwide trends in Kampo use among inpatients with cancer in Japan remain poorly understood. This study aimed to examine the temporal trends and clinical practice patterns of Kampo prescriptions among inpatients with cancer between 2010 and 2023, with a focus on their use in acute or severe conditions.
Methods: This retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including over 6.8 million hospitalizations for five major cancer types (breast, colorectal, gastric, lung, and prostate)between July 2010 and March 2023. Kampo use was identified from in-hospital prescription data. Prescription trends and patient characteristics were analyzed.
Results: Kampo medicines were prescribed in 13.6% of hospitalizations, more commonly among older adults and patients with colorectal cancer. The overall prescription proportion increased from 2010 to 2017 before plateauing. The top five prescribed Kampo medicines were Dai-ken-chu-to, Gosha-jinki-gan, Rikkunshi-to, Shakuyaku-kanzo-to, and Hange-shashin-to. Prescription patterns varied by age group, cancer type, cancer stage, disease status, and cause of hospitalization. Dai-ken-chu-to use shifted from postoperative to chronic care, while Gosha-jinki-gan prescriptions gradually declined.
Conclusions: Kampo prescription patterns among inpatients with cancer have changed over the past fourteen years, reflecting changes in patient demographics and treatment strategies. Kampo medicines appear to be selectively used as supportive care tailored to specific clinical situations. These findings highlight the evolving role of traditional medicine in modern cancer care in Japan.
期刊介绍:
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.